Read Gene

Read Gene Equity Turnover

The Equity Turnover of Read Gene (RDG.WA) as of Oct 16, 2026 is 5.01. In the previous year, Equity Turnover was 4.39 — a change of 14.26% (higher).

Equity Turnover

5.01

YoY

14.26%

Last updated:

Equity Turnover of Read Gene is 2025 5.01 . Equity Turnover of Read Gene was 2024 4.39 . It decreases by 14.26% higher compared to the previous year.

The Read Gene Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
1.54 PLN
Jan 1, 2019
1.27 PLN
Jan 1, 2020
1.33 PLN
Jan 1, 2021
1.19 PLN
Jan 1, 2022
1.31 PLN
Jan 1, 2023
2.44 PLN
Jan 1, 2024
4.39 PLN
Jan 1, 2025
5.01 PLN
The Read Gene Equity Turnover history
YEAREquity TurnoverYoY
5.01+14.26%
4.39+80.04%
2.44+85.46%
1.31+10.35%
1.19-10.67%
1.33+5.27%
1.27-17.62%
1.54+38.50%
1.11-36.76%
1.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA is a biotechnology company based in Szczecin, Poland, operating within the Health Care sector. The company went public via an IPO on February 12, 2009, and is listed under the ticker RDG.WA with ISIN PLRADGN00014. Read Gene SA focuses on medical research and testing, particularly in the fields of chemoprevention, clinical trials, and genetic testing. Its services include specialized tests for breast cancer, colon cancer, and prostate cancer, alongside medical consultancy and DNA testing. The company also provides DNA-related supplements. It operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o., and its major shareholder is GEN-PAT-MED Sp. z o.o. The company's headquarters are located in Szczecin, within the West Pomeranian Voivodeship. Read Gene SA's activities are centered on developing technologies aimed at detecting, preventing, and treating malignant tumors. The company's website is https://read-gene.com/. No additional details regarding founding year, specific products, or financial figures are provided in the source material. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Equity Turnover of Read Gene is 5.01 in 2025.

Equity Turnover of Read Gene changed from 4.39 to 5.01, representing a 14.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Read Gene since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Read Gene

All Key Metrics — Read Gene